Topical IL-1-Ra for Treatment of Corneal Neovascularization

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \> 18 years * Patients with superficial or deep corneal NV that extends farther than 1 mm from the limbus * Patients are in generally good stable overall healthExclusion Criteria: • Has received treatment with anti-VEGF agents (topical, intraocular or systemic) within 30 days of study entry * Corneal or ocular surface infection within 30 days prior to study entry• Ocular or periocular malignancy * Contact lens (excluding bandage contact lens) use within 2 weeks prior to study entry * Persistent epithelial defect (\>1mm and ≥14 days duration) within 2 weeks prior to study entry * Intravitreal or periocular steroids within 2 weeks prior to study entry * Change in dose/frequency of topical steroids and/or NSAIDs within 2 weeks prior to study entry * Pregnancy (positive pregnancy test) or lactation * Premenopausal women not using contraception * Signs of current infection, including fever and current treatment with antibiotics * Participation in another simultaneous medical investigation or trial